...Thank you and good afternoon everybody and welcome to our Q1 2021 quarterly earnings. First, I want to highlight our total revenues for the quarter were $17.4 million or 7% versus 2020. And as you may or may not recall, we had a tough comparison in 2020, because of the pull forward of COVID demand, but it was the wholesalers our patient stocking, which made a presence as we'll talk about in a second look slightly modest increase as much as we would expect quarter-to-quarter, year-over-year. On the JVs and partnerships continue to progress our United Therapeutics collaboration with Tyvaso DPI was submitted to the FDA by United Therapeutics, for both the pulmonary arterial hypertension indication as well as ILD. And we're looking forward to hopefully have an acceptance from the FDA with later this quarter and the approval by year-end. On the pipeline side, we completed our first toxicology studies for clofazimine, which is MNKD-101. We are now just finished dosing the dog study, which is...
